source
- FDA and Capricor clash over Duchenne cell therapy efficacy at advisory committeeAt an FDA advisory committee meeting, the agency and Capricor Therapeutics presented conflicting views on the efficacy data for the company's experimental cell therapy aimed at Duchenne muscular dy…
- Atea's hepatitis C combo therapy shows non-inferior results to Gilead's EpclusaAtea Pharmaceuticals announced that its oral combination of bemnifosbuvir and ruzasvir met the predefined non-inferiority criteria when compared with Gilead's Epclusa for treating hepatitis C. The…